Pharma News

Five Out of Ten Urban Indians are Trying To Lose Weight, a Study by Fitho

  • Posted on: 5 August 2014
  • By: PharmaTutor News

(5th August, 2014; Business Wire India); Studies since 2012 have estimated that over 74% of urban Indians are overweight (i.e. BMI over 23 kg/m2). A recent survey conducted by Fitho, a leading wellness services organization that works with partners like Lal Pathlabs, showed that along with increasing weight, there is also increasing awareness and 5 out of 10 urban Indians are trying to lose weight. While 40% of the overweight people have intent to lose weight but are not taking action to control their weight, the remaining 60% are making an effort to lose weight. The survey revealed that looking good, keeping fit and staying confident are the major reasons for the women and men under 35 to lose weight, while people aged over 35 and the heavily overweight (BMI>25 kg/m2) are doing it primarily for a better health.

US Pharma companies concern about Indian Patent rules

  • Posted on: 31 July 2014
  • By: PharmaTutor News

(31st July, 2014); Indian Patent Act does not allow patent to be granted to inventions involving new forms of a known substance unless it differs significantly in properties with regard to efficacy which is major concern for US pharma companies. This indigenous rules agitated US multinational companies for doing fruitful business in India.

Regeneron's EYLEA® got USFDA approval for treatment of Diabetic Macular Edema

  • Posted on: 31 July 2014
  • By: PharmaTutor News

(31st July, 2014); U.S. Food and Drug Administration (FDA) has approved EYLEA® (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). The recommended dosage of EYLEA in patients with DME is 2 milligrams (mg) every two months (8 weeks) after five initial monthly injections. Although EYLEA may be dosed as frequently as 2 mg every 4 weeks, additional efficacy was not demonstrated when EYLEA was dosed every 4 weeks compared to every 8 weeks.


Now just a single blood test can detect cancer

  • Posted on: 29 July 2014
  • By: PharmaTutor News

(29th July, 2014); It's starting a new era for diagnosis of cancer with a single blood test which bypassing physicians to detect certain symptoms, saving time and preventing costly and unnecessary invasive procedures such as colonoscopies and biopsies. In contrast to present methodologies, it could be a useful aid for investigating patients who are suspected of having a cancer that is currently hard to diagnose.

India stepping ahead with a plan of creating IT enabled Clinical Research Monitoring

  • Posted on: 29 July 2014
  • By: PharmaTutor News

(29th July, 2014); Looking at the current regulatory environment of clinical trial in India, it is important that all information related to 4 major domains i.e, Sponsor/ CRO, Investigator, Ethics Committee, Patient of clinical trials are captured through online in an organized manner. Hence, for ensuring transparency and faster dissemination of information about clinical trials, health ministry may start information technology (IT) enabled platform. The recommendation of such platform is provided by Prof. Ranjit Roy Chaudhary Committee.

PCI disapproved MS Pharmacy courses from any institutions except from NIPERs

  • Posted on: 24 July 2014
  • By: PharmaTutor News

(24th July, 2014); Pharmacy Council of India (PCI) announced in its notification that MS Programmes are not approved by the PCI either for the purpose of registration as a pharmacist under the Pharmacy Act to practice the profession OR any other purpose like teaching in approved pharmacy institutions.

Gene transplantation in injured heart develops biological pacemakers

  • Posted on: 21 July 2014
  • By: PharmaTutor News

(21st July, 2014); Cardiologists at the Cedars-Sinai Heart Institute have developed a minimally invasive gene transplant procedure that changes unspecialized heart cells into “biological pacemaker” cells that keep the heart steadily beating.

Google & Novartis join hands for development of SMART LENS

  • Posted on: 21 July 2014
  • By: PharmaTutor News

(21st July, 2014); Novartis & Google join together to develop smart contact lens which will be useful in monitoring blood sugar level for diabetic patients and restore focusing capacity of eyes in patients with presbyopia. Alcon, eye care division of Novartis, has entered into an agreement with a division of Google Inc. to in-license its “smart lens” technology for all ocular medical uses.

Pages